Arrowhead Pharmaceuticals Inc logo

Arrowhead Pharmaceuticals Inc(ARWR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$43.11
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ARWR

11/18/2026: ARWR (1-star) is currently NOT-A-BUY. Pass it for now.

Arrowhead Pharmaceuticals is a clinical and commercial-stage biotechnology company that utilizes its proprietary Targeted RNAi Molecule platform to develop medicines that silence genes causing intractable diseases. The company's main strengths include versatile delivery technology, lucrative pharmaceutical partnerships, and the recent commercial launch of its first approved drug, REDEMPLO. Its primary growth story centers on expanding plozasiran into larger cardiometabolic markets like severe hypertriglyceridemia. However, the company faces substantial risks from high research cash burn, operating losses, and intense competition from established genetic medicine rivals. The stock suits growth-oriented investors willing to tolerate high volatility, with ongoing commercial adoption and regulatory updates serving as key developments to monitor.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company features high-growth potential anchored by a robust clinical pipeline and early-stage commercial product rollouts.
Momentum investorStrong fit while signal remains positiveStock performance reacts sharply to clinical trial readouts, regulatory milestones, and commercial adoption updates.
Value investorWeak fitArrowhead currently operates at a net loss as it prioritizes reinvestment into R&D rather than immediate earnings.
Dividend investorWeak fitThe company does not pay dividends, retaining all capital to fund drug development and commercial expansion.
Low-risk investorWeak fitHigh clinical trial risks, regulatory binary events, and high share price volatility characterize the stock profile.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences sharp price swings reacting to clinical trial data, regulatory updates, and market sentiment.
Valuation riskMedium / highValuation heavily depends on long-term commercial projections for pipeline assets rather than current earnings.
Competition risk (RNAi and genetic medicine rivals)HighIntense competition from well-capitalized biotechnology peers targeting the same genetic pathways can threaten market share.
Business qualityMedium / highThe company possesses a highly innovative proprietary platform, though commercial sustainability is still in its early phases.
Dividend incomeLow / noneNo dividend is paid to shareholders.
Execution riskHighSuccess relies heavily on executing commercial launches, regulatory approvals, and complex clinical trials smoothly.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 6.08B USD
Price to earnings Ratio -
1Y Target Price 105.86
Price to earnings Ratio -
1Y Target Price 105.86
Volume (30-day avg) 2.1M shares
Beta 1.37
52 Weeks Range 37.06 - 95.49
Updated Date 11/18/2026
52 Weeks Range 37.06 - 95.49
Updated Date 11/18/2026
Dividends yield (FY) -
Basic EPS (TTM) -5.11

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
62.3%
Active BUY / eligible
66 / 106
30-Day BUY Count Change
+23
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.6%
Active BUY / eligible
17 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -16.92%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ARWR receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
ARWR has moderate overall fundamentals (3 stars), with moderate financial health, weak growth momentum, and solid ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: negative earnings growth (-44302.6%), weak cash generation (FCF margin -63.0%), negative revenue growth (-45.6%).

Financial Health Rating

★★★★★
ARWR's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 56.3%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
ARWR's growth profile is soft, with the least-weak measure being revenue growth at -45.6% FY2026 versus FY2025. By comparison, while earnings growth (-44302.6%, negative) and free-cash-flow growth (-281.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 86.8% and approximately 86.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.65% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 10.50%
venBio Select Advisor LLC 8.04%
FMR Inc 5.69%
Vanguard Portfolio Management, LLC 4.50%
Vanguard Capital Management, LLC 4.33%

Unit Economics (Per $1K Revenue)

★★★★★
ARWR generates approximately $996 of gross profit, $-1,569 of operating income, and $-630 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.94%

Quantitative Style Profile

★★★★★
ARWR has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercial Product SalesInitial global sales of approved specialty therapeutics like REDEMPLO for rare genetic disorders.Represents the emerging, recurring foundation of long-term commercial revenues.
Collaboration and License AgreementsUpfront licensing fees, research funding, and milestone payments from major pharmaceutical partners.Provides non-dilutive capital injections that help offset heavy clinical research expenses.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 111.11
Enterprise Value 6.06B
Price to Sales(TTM) 13.48
Enterprise Value 6.06B
Price to Sales(TTM) 13.48
Enterprise Value to Revenue 13.44
Enterprise Value to EBITDA 27.85
Shares Outstanding 141.37M
Shares Floating 122.56M
Shares Outstanding 141.37M
Shares Floating 122.56M
Percent Insiders 3.65
Percent Institutions 86.78

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.